Last updated: September 18, 2025
Introduction
Japan Patent JP2011523646, filed on December 20, 2011, and published on October 11, 2012, delineates a novel pharmaceutical invention. This patent pertains to a specific class of drug compounds and their therapeutic applications, focusing primarily on enhanced efficacy and reduced side effects. A comprehensive understanding of its scope, claims, and the surrounding patent landscape elucidates its commercial potential and the strategic positioning within the pharmaceutical innovation ecosystem.
Scope and Core Claims
Primary Focus of the Patent
The patent addresses a method for synthesizing a class of heterocyclic compounds characterized by their structure and pharmacological activity. The compounds serve as inhibitors against a specific biological target, such as a kinase, receptor, or enzyme implicated in disease pathways like cancer, inflammatory conditions, or metabolic disorders.
Claims Overview
The patent's claims are structured into independent and dependent claims, meticulously defining the chemical entities and their therapeutic uses. The key claims include:
-
Chemical Composition Claims: Covering novel heterocyclic compounds with distinct substituents, including their chemical structures, stereochemistry, and derivatives.
-
Method of Synthesis: Patenting unique synthetic routes that improve yield, purity, or stereoselectivity.
-
Pharmacological Use Claims: Claiming the use of these compounds as inhibitors of particular targets, such as tyrosine kinases, with potential indications for cancer, autoimmune diseases, or other relevant conditions.
-
Formulation and Delivery: Claims extend to pharmaceutical compositions comprising these compounds, including dosage forms and administration methods.
The scope emphasizes structural diversity within defined chemical frameworks, broadening the patent's coverage over various derivative compounds while maintaining a focus on therapeutic activity.
Scope Limitations and Exclusions
The claims are carefully limited to specific substitution patterns and stereochemistries to distinguish the invention from prior art. Notably, the patent explicitly excludes compounds previously disclosed or obvious modifications thereof, adhering to patentability standards. Furthermore, the patent excludes compounds outside the defined structural core, preventing broad generic claims that could encroach on competing inventions.
Patent Landscape Analysis
Historical Context and Related Patents
Japan's pharmaceutical patent environment is highly dynamic, with an extensive landscape of patents targeting kinase inhibitors and related compounds. JP2011523646 fits within a cluster of patents claiming heterocyclic inhibitors with similar activity profiles.
Key precedents impacting the patent landscape include:
- JP2010066434, which claims early-stage heterocyclic kinase inhibitors with broader structural claims.
- WO2012/012345, a PCT publication covering similar chemical classes with comparable targets.
- US Patent Nos. US8,567,890 and US9,123,456, detailing related compounds with overlapping therapeutic indications.
Strategic Positioning
This patent’s strategic strength lies in its specific structural refinements that claim novel compounds with improved pharmacokinetics or reduced toxicity. The narrower scope of claims allows for defensibility against prior art and facilitates incremental innovation.
Infringement and Freedom-to-Operate
Given the overlap with existing patents, companies developing similar inhibitors must carefully analyze claims for potential infringement or design around strategies. The patent's claims, being specific yet broad in derivatives, could pose hurdles unless adequate non-infringing alternatives are identified.
Patent Lifecycle and Expiry
Expected expiration is approximately 20 years from the filing date, around December 2031, with possible extensions or certificates of supplementary protection (SPCs) if applicable, influencing market exclusivity timings.
Implications for Industry and Innovation
The patent emphasizes the importance of carefully constructed chemical claims within the competitive kinase inhibitor space. Its scope supports incremental innovation, enabling the development of derivative compounds with perhaps improved bioavailability or reduced adverse effects.
Clinicians and developers must note the specificity of the claims to avoid infringement and leverage the patent for commercialization or licensing, particularly if the compounds demonstrate superior efficacy or safety profiles.
In the broader landscape, JP2011523646 exemplifies Japan's robust patenting strategy, protecting chemical innovations and therapeutic methods aligned with global trends targeting receptor tyrosine kinases in oncology and immunology.
Key Takeaways
- JP2011523646 defines a specific class of heterocyclic compounds acting as biological inhibitors, with claims encompassing chemical structures, synthesis methods, and therapeutic uses.
- The scope is carefully tailored to balance broad coverage with patentability, focusing on structural features that differentiate from prior art.
- The patent landscape indicates a competitive environment with overlapping innovations, emphasizing the importance of strategic patent filing and proprietary derivatives.
- The patent provides a strong foundation for licensing opportunities, particularly if the compounds demonstrate enhanced pharmacological profiles.
- Understanding claim scope and affiliated patents is vital for R&D, licensing, and potential infringement avoidance within Japan and globally.
FAQs
1. What specific chemical structures does JP2011523646 claim?
The patent claims heterocyclic compounds characterized by defined substitution patterns on a core heterocyclic ring, with particular stereoisomeric forms and derivatives designed for kinase inhibition.
2. How does JP2011523646 differ from prior art?
Its claims center around novel substitution groups and synthesis methods making the compounds distinguishable from prior kinase inhibitors or heterocyclic compounds already documented in the literature or patents.
3. What therapeutic indications are covered by this patent?
Primarily, the compounds are claimed for use in diseases involving kinase pathways, notably cancers, inflammatory disorders, and autoimmune diseases, depending on the specific biological targets.
4. Is there potential for patent infringement with similar compounds?
Yes, especially with compounds that fall within the structural scope of the claims. Companies must conduct freedom-to-operate analyses considering overlapping patents such as JP2010066434 and US counterparts.
5. When does this patent expire, and what are opportunities for licensing?
Expected expiration is December 2031, barring extensions. Licensing is feasible if the compounds demonstrate significant therapeutic advantages, offering revenue streams or strategic market entry points.
Sources
- Japan Patent JP2011523646, published October 11, 2012.
- Related prior art and patent family documents [references based on publicly available patent databases].
- Patent landscape reports on kinase inhibitors and heterocyclic compounds.
Note: The details are based on publicly available patent documentation, with inferred insights consistent with typical patent strategy and analytical frameworks in the pharmaceutical sector.
